Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0015436031
Thu, 10.02.2022
CureVac
CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
- Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains
- Influenza candidate developed in collaboration with [ … ]
Mon, 17.01.2022
CureVac
CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry
TÜBINGEN, Germany/ BOSTON, USA - January 17, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the company's Chief Technology Offic [ … ]
Thu, 18.11.2021
CureVac
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update
- Strategic focusing on second-generation mRNA program jointly developed with GSK after withdrawal of first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review
- Nature publication of promising pre-clinical resu [ … ]
Thu, 18.11.2021
CureVac
CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
TÜBINGEN, Germany/ BOSTON, USA - November 18, 2021 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ri [ … ]
Wed, 10.11.2021
CureVac
CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response
- Immune profiling of clinical trial participants in Phase 1 dose-escalation study shows immune response in both injected and non-injected lesions
- Expansion part of Phase 1 study fully recruited; results expected in the secon [ … ]
Tue, 12.10.2021
CureVac
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
- COVID-19 vaccine efforts to be re-allocated to accelerate the development of second-generation program in collaboration with GSK
- First-generation vaccine candidate, CVnCoV, to be withdrawn from regulatory review due to potential overlap with approval t [ … ]
Tue, 14.09.2021
CureVac
CureVac Streamlines European Network for mRNA Product Manufacturing
CureVac right-sizes manufacturing network to adapt to changes in vaccine peak demands
Demand reassessed for first-generation COVID-19 vaccine candidate, CVnCoV, currently under regulatory review with EMA
Contracts with manufacturing partners WACKER and Celonic terminated; Rentsc [ … ]
Tue, 31.08.2021
CureVac
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
TÜBINGEN, Germany/ BOSTON, USA - August 31, 2021 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the publication of its pivotal Phase 2b/3 ( [ … ]
Mon, 30.08.2021
CureVac
CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic
- Findings in preclinical mouse models provide first direct proof of efficacy of HNF4A mRNA therapeutics in the treatment of liver fibrosis and cirrhosis
- Further research aimed at optimizing mRNA therapeutic candidates for non-clinical and clini [ … ]
Mon, 16.08.2021
CureVac
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
Continuation of corporate transformation into commercial-ready biopharma company
Management team strengthened with appointments of Chief Operating Officer Malte Greune and Chief Development Officer Klaus Edvardsen
First-generation C [ … ]